Clinical Trials Browser

Phase 1 × INDUSTRY × ON 01910 × Clear all

Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00861783 2017-06-23

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Phase 1 Completed

16 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01125891 2017-06-23

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Phase 1 Completed

39 enrolled

Other neoplasmOther solid neoplasm

Malignant Neoplasmas

NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Phase 1 Completed

10 enrolled

Tumor-Agnostic

Neoplasms

NCT01168011 2017-06-23

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Phase 1 Completed

68 enrolled

Other solid neoplasm

Solid Tumor

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Phase 1 Completed

42 enrolled

Tumor-Agnostic

Neoplasms

NCT02107235 2017-06-23

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Phase 1 Completed

2 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer